Biocon targets 2027 EU and UK launch for breast cancer biosimilar
In short
Biocon said its breast cancer biosimilar is aiming for a launch in the EU and UK in the first quarter of 2027. It then expects a US launch in the third quarter of 2028, after a deal with Genentech.
This matters because it gives the company a clearer launch path in big markets. The report does not say the product name or the deal details.
What the reporting says
Biocon said its breast cancer biosimilar is targeting a first-quarter 2027 launch in the European Union and the UK, followed by the US in the third quarter of 2028. The company got launch clarity after a deal with Genentech, according to the reporting. The source does not state the product name or commercial terms. The immediate consequence is a clearer timeline for market entry in major regions.
Why it matters
Biocon has received launch clarity for a breast cancer biosimilar after a deal with Genentech. The company is targeting the first quarter of 2027 for launches in the European Union and the UK, followed by the US in the third quarter of 2028. That creates a clearer regulatory and commercial path, but the reporting does not provide pricing, product naming or deal economics.